



Receipt

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q85416

Motonori MIYAKAWA, et al.

Appln. No.: 10/518,405

Group Art Unit: Not Yet Assigned

Confirmation No.: 8028

Examiner: Not Yet Assigned

Filed: November 18, 2005

For: ANDROGEN RECEPTOR AGONISTS

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

ATTN: Office of Initial Patent Examination

Filing Receipt Correction

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

We enclose a copy of the Official Filing Receipt for the above-identified application and request the following corrections:

TOT CLMS

43 29

Foreign Applications

JAPAN

179088/2002

June 19, 2002


REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Appln. No.: 10/518,405

Atty. Docket No.: Q85416

Verification for the requested corrections is indicated on the Declaration and Assignment
filed November 18, 2005 and December 17, 2004 letter to the Commissioner for Patents.

Respectfully submitted,



Susan J. Mack

Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: May31, 2006



FILING RECEIPT

PLEASE DATE STAMP AND RETURN TO US - BOX 235X

In re application of

Motonori MIYAKAWA, et al.

Appln. No.: 10/518,405

Group Art Unit: Not Yet Assigned

Confirmation No.: 8028

Examiner: Not Yet Assigned

Filed: November 18, 2005

For: ANDROGEN RECEPTOR AGONISTS

PAPER(S) FILED ENTITLED:

1. Request for Corrected Official Filing Receipt
2. Marked up copy of Official Filing Receipt
3. Copy of December 17, 2004 letter to the Commissioner for Patents
4. Declaration and Power of Attorney
5. Assignment

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

DOCKET NO.: Q85416

ATTORNEY/SEC: Susan J. Mack/laj

Date Filed: May 31, 2006

WASHINGTON OFFICE

23373

CUSTOMER NUMBER



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/518,405	11/18/2005	1614	2510	Q85416	18	1329	1

CONFIRMATION NO. 8028

23373
SUGHRUE MION, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
SUITE 800
WASHINGTON, DC 20037

FILING RECEIPT



OC000000017912517

Date Mailed: 01/31/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Motonori Miyakawa, Kyoto, JAPAN;
Yuji Sumita, Kyoto, JAPAN;
Kazuyuki Furuya, Kyoto, JAPAN;
Kiyonoshin Ichikawa, Kyoto, JAPAN;
Noriko Yamamoto, Kyoto, JAPAN;
Seiji Amano, Kyoto, JAPAN;
Hiroaki Nejishima, Kyoto, JAPAN;
Keigo Hanada, Shiga, JAPAN;

Assignment For Published Patent Application

KAKEN PHARMACEUTICAL CO., LTD., TOKYO, JAPAN

Power of Attorney: The patent practitioners associated with Customer Number 23373.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/07799 06/19/2003

Foreign Applications

JAPAN 179088/2002 June 19, 2002

Projected Publication Date: 05/04/2006

Non-Publication Request: No

Early Publication Request: No

Title

Androgen receptor agonists

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted

under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



Susan J. Mack
T (202) 663-7943
smack@sughrue.com

2100 Pennsylvania Avenue, NW
Washington, DC 20037-3213
T 202.293.7060
F 202.293.7860

401 Castro Street
Mountain View, CA 94041-2007
T 650.625.8100
F 650.625.8110

AIG Bldg. 14F
1-1-3 Marunouchi
Chiyoda-ku Tokyo 100-0005
Japan
T 03.5220.0200
F 03.5220.0222

December 17, 2004

MAIL STOP PCT

Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

PCT/JP03/07799
-filed June 19, 2003

www.sughrue.com

Re: Application of Motonori MIYAKAWA, Yuji SUMITA, Kazuyuki FURUYA,
Kiyonoshin ICHIKAWA, Noriko YAMAMOTO, Keigo HANADA, Seiji
AMANO and Hiroaki NEJISHIMA
ANDROGEN RECEPTOR AGONISTS
Assignee: **KAKEN PHARMACEUTICAL CO., LTD.**
Our Ref: Q85416

Dear Sir:

The following documents and fees are submitted herewith in connection with the above application for the purpose of entering the National stage under 35 U.S.C. §371 and in accordance with the Patent Cooperation Treaty:

- ☒ a copy of the executed Declaration and Power of Attorney.
- ☒ an English translation of the International Application.
- ☒ 18 sheet(s) of drawings.
- ☒ a copy of the executed Assignment and PTO 1595 form.
- ☒ a PTO/SB/08 A & B (modified) listing the ISR/IPER references.
- ☒ a Preliminary Amendment.
- ☒ **it is expressly requested that the national stage of processing be commenced immediately in accordance with 35 U.S.C. § 371(f)**

It is assumed that copies of the International Application, the International Search Report and cited references, the International Preliminary Examination Report, and any Articles 19 and 34 amendments as required by §371(c) will be supplied directly by the International Bureau, but if further copies are needed, the undersigned will undertake to provide them upon request.



SUGHRUE MION, PLLC

National Stage Application
of PCT/JP03/07799
-filed June 19, 2003

Q85416

The Government filing fee is calculated as follows:

Total claims	<u>29</u>	-	20	=	<u>9</u>	x	\$50.00	=	<u>\$450.00</u>
Independent claims	<u>1</u>	-	3	=	<u></u>	x	\$200.00	=	<u>\$0.00</u>
Filing Fee									\$300.00
Examination Fee									\$200.00
Search Fee									\$500.00
Multiple Dependent Claim Fee									\$360.00
TOTAL FILING FEE									<u>1,810.00</u>
Recordation of Assignment									<u>\$40.00</u>
TOTAL FEE									<u>\$1,850.00</u>

Checks for the statutory filing fee of \$1,810.00 and Assignment recordation fee of \$40.00 are attached. The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this transmittal letter is attached.

Priority is claimed from:

<u>Country</u>	<u>Application No</u>	<u>Filing Date</u>
Japan	179088/2002	June 19, 2002

Respectfully submitted,

Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: December 17, 2004

DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

As a below named inventor, I hereby declare that: My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

ANDROGEN RECEPTOR AGONISTS

the application of which

☐ is attached hereto

OR

☒ was filed on June 19, 2003 as United States Application Number or PCT International Application Number PCT/JP03/07799 (Confirmation No. _____), and was amended on _____ (if applicable).



I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part application(s), material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application(s) having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date	Priority Claimed	
			Yes	No
<u>179088/2002</u>	<u>Japan</u>	<u>June 19, 2002</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

I hereby claim domestic priority benefits under 35 United States Code §120 of any United States application(s), §119(e) of any United States provisional application(s), or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S. or International Application Number(s)	U.S. or International Filing Date	Status

I hereby appoint all attorneys of **SUGHRUE MION, PLLC** who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of Sughrue Mion, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.



23373

PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


NAME OF SOLE OR FIRST INVENTOR:			
Given Name (first and middle [if any]) Motonori		Family Name or Surname MIYAKAWA	
Inventor's Signature <i>Mr. Motonori Miyakawa</i>		Date 11/4/04	
Residence: City Kyoto	State	Country Japan	Citizenship Japanese
c/o CENTRAL RESEARCH LABORATORIES, KAKEN PHARMACEUTICAL CO., LTD. of			
Mailing Address: 14, Shinomiyaminamigawara-cho, Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan			
City Kyoto	State	Zip 607-8042	Country Japan
NAME OF SECOND INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF THIRD INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF FOURTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF FIFTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country

DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

As a below named inventor, I hereby declare that: My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

ANDROGEN RECEPTOR AGONISTS

the application of which

☐ is attached hereto

OR

☒ was filed on June 19, 2003 as United States Application Number or PCT International Application Number PCT/JP03/07799 (Confirmation No. _____), and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part application(s), material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application(s) having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)

Country

Foreign Filing Date

Priority Claimed

Yes

No

179088/2002JapanJune 19, 2002☒☐

I hereby claim domestic priority benefits under 35 United States Code §120 of any United States application(s), §119(e) of any United States provisional application(s), or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S. or International Application Number(s)

U.S. or International Filing Date

Status


I hereby appoint all attorneys of **SUGHRUE MION, PLLC** who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of Sughrue Mion, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.



23373

PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


NAME OF SOLE OR FIRST INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Keigo		HANADA	
Inventor's Signature		Date	
		November 4, 2004	
Residence: City	State	Country	Citizenship
Shiga		Japan	Japanese
Mailing Address: 2-1-38, Hirai, Kusatsu-shi, Shiga 525-0023 Japan			
City	State	Zip	Country
Shiga		525-0023	Japan
NAME OF SECOND INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF THIRD INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF FOURTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF FIFTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country

DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

As a below named inventor, I hereby declare that: My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

ANDROGEN RECEPTOR AGONISTS

the application of which
☐ is attached hereto



OR

☒ was filed on June 19, 2003 as United States Application Number or PCT International Application Number PCT/JP03/07799 (Confirmation No. _____), and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part application(s), material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application(s) having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date	Priority Claimed	
			Yes	No
<u>179088/2002</u>	<u>Japan</u>	<u>June 19, 2002</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

I hereby claim domestic priority benefits under 35 United States Code §120 of any United States application(s), §119(e) of any United States provisional application(s), or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S. or International Application Number(s)	U.S. or International Filing Date	Status
_____	_____	_____

I hereby appoint all attorneys of **SUGHRUE MION, PLLC** who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of Sughrue Mion, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.



23373

PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR:			
Given Name (first and middle [if any]) Yuji		Family Name or Surname SUMITA	
Inventor's Signature <i>Yuji Sumita</i>		Date November 4, 2004	
Residence: City Kyoto	State	Country Japan	Citizenship Japanese
c/o CENTRAL RESEARCH LABORATORIES, KAKEN PHARMACEUTICAL CO., LTD. of			
Mailing Address: 14, Shinomiyaminamigawara-cho, Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan			
City Kyoto	State	Zip 607-8042	Country Japan
NAME OF SECOND INVENTOR:			
Given Name (first and middle [if any]) Kazuyuki		Family Name or Surname FURUYA	
Inventor's Signature <i>Kazuyuki Furuya</i>		Date November 4, 2004	
Residence: City Kyoto	State	Country Japan	Citizenship Japanese
c/o CENTRAL RESEARCH LABORATORIES, KAKEN PHARMACEUTICAL CO., LTD. of			
Mailing Address: 14, Shinomiyaminamigawara-cho, Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan			
City Kyoto	State	Zip 607-8042	Country Japan
NAME OF THIRD INVENTOR:			
Given Name (first and middle [if any]) Kiyonoshin		Family Name or Surname ICHIKAWA	
Inventor's Signature <i>Kiyonoshin Ichikawa</i>		Date November 4, 2004	
Residence: City Kyoto	State	Country Japan	Citizenship Japanese
c/o CENTRAL RESEARCH LABORATORIES, KAKEN PHARMACEUTICAL CO., LTD. of			
Mailing Address: 14, Shinomiyaminamigawara-cho, Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan			
City Kyoto	State	Zip 607-8042	Country Japan
NAME OF FOURTH INVENTOR:			
Given Name (first and middle [if any]) Noriko		Family Name or Surname YAMAMOTO	
Inventor's Signature <i>Noriko Yamamoto</i>		Date November 4, 2004	
Residence: City Kyoto	State	Country Japan	Citizenship Japanese
c/o CENTRAL RESEARCH LABORATORIES, KAKEN PHARMACEUTICAL CO., LTD. of			
Mailing Address: 14, Shinomiyaminamigawara-cho, Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan			
City Kyoto	State	Zip 607-8042	Country Japan
NAME OF FIFTH INVENTOR:			
Given Name (first and middle [if any]) Seiji		Family Name or Surname AMANO	
Inventor's Signature <i>Seiji Amano</i>		Date November 4, 2004	
Residence: City Kyoto	State	Country Japan	Citizenship Japanese
c/o CENTRAL RESEARCH LABORATORIES, KAKEN PHARMACEUTICAL CO., LTD. of			
Mailing Address: 14, Shinomiyaminamigawara-cho, Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan			
City Kyoto	State	Zip 607-8042	Country Japan

NAME OF SIXTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Hiroaki		NEJISHIMA	
Inventor's Signature		Date	
<i>Hiroaki Nejishima</i>		November 4, 2004	
Residence: City	State	Country	Citizenship
Kyoto		Japan	Japanese
Mailing Address: c/o CENTRAL RESEARCH LABORATORIES, KAKEN PHARMACEUTICAL CO., LTD. of			
14, Shinomiyaminami-gawara-cho, Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan			
City	State	Zip	Country
Kyoto		607-8042	Japan
NAME OF SEVENTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City		State	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF EIGHTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City		State	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF NINTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City		State	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF TENTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City		State	Citizenship
Mailing Address:			
City	State	Zip	Country

MODIFIED Form PTO-1595
(Rev. 10/02)RECORDATION FORM COVER SHEET
PATENTS ONLYU.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

To the Director of the U.S. Patent and Trademark Office: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Motonori MIYAKAWA
Yuji SUMITA
Kazuyuki FURUYA
Kiyonoshin ICHIKAWA
Noriko YAMAMOTO
Keigo HANADA
Seiji AMANO
Hiroaki NEJISHIMA

2. Name and address of receiving party(ies):

KAKEN PHARMACEUTICAL CO., LTD.
28-8, Honkomagome 2-chome,
Bunkyo-ku, Tokyo
113-8650 JapanAdditional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other _____

Execution Date: November 4, 2004

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: November 4, 2004

A. Patent Application No.(s) This Form 1595 is
being filed with a new application. Therefore, no
U.S. Application No. has been assigned.

B. Patent No.(s)

Additional numbers attached? ☐ Yes ☒ No5. Name and address of party to whom correspondence
concerning document should be mailed:

SUGHRUE MION, PLLC

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

6. Total number of applications and patents involved:

1

7. Total fee (37 CFR 3.41): \$40.00

- ☒ Enclosed.
☐ Authorized to be charged to Deposit Account No. 19-4880.

The USPTO is directed and authorized to charge all required
fees, except for the Issue Fee and the Publication Fee, to Deposit
Account No. 19-4880. Please also credit any overpayments to said
Deposit Account.

8. Deposit Account Number:

19-4880

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the
original document.

Susan J. Mack

Reg. No. 30,951

December 17, 2004

Date

Total number of pages including cover sheet, attachments, and documents: 4

Mail documents to be recorded with required cover sheet information to:

MAIL STOP ASSIGNMENT RECORDATION SERVICES

Director of the U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

Assignment

Whereas, I/We, Motonori MIYAKAWA of
c/o CENTRAL RESEARCH LABORATORIES, KAKEN PHARMACEUTICAL CO., LTD. of
14, Shinomiyaminamigawara-cho, Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan
hereinafter called assignor(s), have invented certain improvements in
ANDROGEN RECEPTOR AGONISTS

and executed an application for Letters Patent of the United States of America therefor on
November 4, 2004; and

Whereas, KAKEN PHARMACEUTICAL CO., LTD.
of 28-8, Honkomagome 2-chome,
Bunkyo-ku, Tokyo 113-8650 Japan

(assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. §119, and I/we request the Director – U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request our attorneys SUGHRUE MION, PLLC of 2100 Pennsylvania Avenue, NW, Washington, DC 20037-3213 to insert here in parentheses (Application number _____ and Confirmation number _____, filed _____) the filing date and application number of said application when known.

Date:

11/4/04

s/ Motonori MIYAKAWA

Date:

s/

Date:

s/

Date:

s/

Assignment

Whereas, I/We, Keigo HANADA of
2-1-38, Hirai, Kusatsu-shi, Shiga 525-0023 Japan
hereinafter called assignor(s), have invented certain improvements in
ANDROGEN RECEPTOR AGONISTS

and executed an application for Letters Patent of the United States of America therefor on
November 4, 2004; and

Whereas, KAKEN PHARMACEUTICAL CO., LTD.
of 28-8, Honkomagome 2-chome,
Bunkyo-ku, Tokyo 113-8650 Japan

(assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. §119, and I/we request the Director – U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request our attorneys SUGHRUE MION, PLLC of 2100 Pennsylvania Avenue, NW, Washington, DC 20037-3213 to insert here in parentheses (Application number _____ and Confirmation number _____, filed _____) the filing date and application number of said application when known.

Date: November 4, 2004

s/ Keigo HANADA

Date: _____

s/

Date: _____

s/

Date: _____

s/

Assignment

Whereas, I/We, Yuji SUMITA, Kazuyuki FURUYA, Kiyonoshin ICHIKAWA,
Noriko YAMAMOTO, Seiji AMANO and Hiroaki NEJISHIMA of c/o CENTRAL RESEARCH
LABORATORIES, KAKEN PHARMACEUTICAL CO., LTD. of 14, Shinomiyaminamigawara-cho,
Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan, respectively,

hereinafter called assignor(s), have invented certain improvements in
ANDROGEN RECEPTOR AGONISTS

and executed an application for Letters Patent of the United States of America therefor on _____; and

Whereas, KAKEN PHARMACEUTICAL CO., LTD. of 28-8, Honkomagome 2-chome,
Bunkyo-ku, Tokyo 113-8650 Japan

(assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. §119, and I/we request the Director – U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request our attorneys SUGHRUE MION, PLLC of 2100 Pennsylvania Avenue, NW, Washington, DC 20037-3213 to insert here in parentheses (Application number _____ and Confirmation number _____, filed _____) the filing date and application number of said application when known.

Date: November 4, 2004 Yuji Sumita
s/ Yuji SUMITA

Date: November 4, 2004 Kazuyuki Furuya
s/ Kazuyuki FURUYA

Date: November 4, 2004 Kiyonoshin Ichikawa
s/ Kiyonoshin ICHIKAWA

Date: November 4, 2004 Noriko Yamamoto
s/ Noriko YAMAMOTO

Date: November 4, 2004 Seiji Amano
s/ Seiji AMANO

Date: November 4, 2004 Hiroaki Nejishima
s/ Hiroaki NEJISHIMA

Date: